

Melanoma

September 9, 2006
New York, NY

Symposium Overview and Purpose

The incidence of melanoma has been increasing rapidly—by a factor of about 15 in the past 6 decades—creating a need for effective novel therapies. The prognosis of melanoma spans the spectrum from being almost completely curable if detected early to being lethal in more advanced stages of the disease. Many efforts have been made to improve the treatment options for patients with malignant melanoma. To improve clinical outcomes for melanoma, researchers have combined biologic agents with chemotherapy agents for advanced-stage disease. Despite the improvement in treatment modalities, approximately 8000 deaths are attributable to melanoma each year in the United States. The purpose of this symposium is to discuss emerging therapeutic strategies, including the current status of both adjuvant and neoadjuvant treatments with vaccines and biochemotherapy regimens for early-stage disease. In addition, the clinical utility of biologic therapies and the role of novel targeted agents in the clinical management of advanced malignant melanoma will be assessed.

Target Audience

This symposium is designed primarily for medical oncologists, dermatologists, surgical oncologists, oncology nurses, and other health care professionals interested in the treatment of melanoma. Fellows in training with research and patient management interests in melanoma are also invited to attend.

CME Accreditation and Designation

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives

At the conclusion of this symposium, you should be able to:

- Assess current diagnostic techniques for early detection of melanoma
- Summarize the role of sentinel node biopsy in the surgical management of melanoma
- Discuss the current standard of care for the management of metastatic melanoma
- Evaluate the novel targeted agents for the treatment of melanoma
- Review current advances in adjuvant and neoadjuvant therapies for patients with melanoma

A D V A N C E S I N

NewYork-Presbyterian Hospital/
Columbia University Medical Center

COMPLIMENTARY REGISTRATION

CHAIRMAN

Howard Kaufman, MD

Vice Chairman of Surgical Oncology
Department of Surgery
Columbia University College of
Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, NY

FACULTY

Anna Pavlick, MD

Assistant Professor of Medicine
and Dermatology
New York University Medical Center
New York, NY

Bret Taback, MD

Assistant Professor of Clinical Surgery
Columbia University College of
Physicians and Surgeons
New York, NY

Horatio Wildman, MD

Assistant Professor of Dermatology
Weill Medical College of
Cornell University
New York, NY

Jedd Wolchok, MD, PhD

Assistant Attending Physician Memorial
Sloan-Kettering Cancer Center
Assistant Professor of Medicine
Will Medical College of Cornell University
Associate Director, The Ludwig Center for
Cancer Immunotherapy



Supported by
educational grant from

Agenda

- 9:00 am **Registration and Breakfast**
- 9:30 am **Welcome and Introductions**
Howard Kaufman
- 9:35 am **Early Detection of Melanoma**
Horatio Wildman
- 10:00 am **Sentinel Node Biopsy and Other Surgical Issues in Management of Melanoma**
Bret Taback
- 10:25 am **Treatment for Metastatic Melanoma: Current Standard of Care**
Howard Kaufman
- 10:50 am **Targeted Therapy of Melanoma**
Anna Pavlick
- 11:15 am **Adjuvant and Neoadjuvant Therapy for Melanoma**
Jedd Wolchok
- 11:40 am **Panel Discussion**
- 12:00 pm **Adjourn**

CHAIRMAN

Howard Kaufman, MD
NewYork-Presbyterian Hospital
New York, NY

FACULTY

Anna Pavlick, MD
New York University Medical Center
New York, NY

Bret Taback, MD
Columbia University College of
Physicians and Surgeons
New York, NY

Horatio Wildman, MD
Weill Medical College of
Cornell University
New York, NY

Jedd Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

VENUE

**NewYork-Presbyterian Hospital/
Columbia University Medical Center**
Milstein Hospital Building
177 Fort Washington Ave.,
New York, NY 10032

COMPLIMENTARY REGISTRATION

September 9, 2006 **New York, NY**

ADVANCES IN Melanoma

First Name _____ Middle Initial _____ Last Name _____

Physician PA-C NP Industry* Other _____

Birth Date (MM/DD) _____ Mailing Address _____

Suite _____ City _____ State _____ Postal/Zip Code _____ Country _____

Phone Number _____ Fax _____

(Must be provided: your confirmation will be sent by fax.)

E-mail _____

(Must be provided: your CME certificate will be sent by e-mail.)

Specialty _____

Check here if you have any special dietary needs.

Please specify: _____

Physicians' Education Resource
CME Department
3500 Maple Ave., Suite 700
Dallas, TX 75219
Phone: (888) 949-0045
Fax: (214) 367-3305
E-mail: CME@pergroupip.com
www.Melanoma.CancerConferences.com

* **INDUSTRY** is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical. Industry registrations **cannot** be processed online. To request attendance at a symposium, registration can be submitted via fax, phone, or e-mail. For more information, e-mail us at CME@pergroupip.com.

_____ Initial here if you wish to be informed of other PER educational activities.

**FOR MORE INFORMATION AND REGISTRATION, PLEASE VISIT US ONLINE AT
www.Melanoma.CancerConferences.com.**